Please login to the form below

Not currently logged in

biliary tract cancer

This page shows the latest biliary tract cancer news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer

AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer

AstraZeneca's (AZ) Imfinzi (durvalumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat biliary tract cancer (BTC) in combination with chemotherapy, the company announced. ... London Cancer Institute, and

Latest news

More from news
Approximately 4 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    This treatment quickly became the ‘gold standard’ for women with metastatic breast cancer. ... biliary tract cancer as well as other solid tumours.

  • Pharma deals continue to slide Pharma deals continue to slide

    Mundipharma built its oncology franchise following the acquisition of an old anti-cancer drug and the deal to license a phase 3 product for biliary tract cancer will provide a new ... CAP7.1 prodrug of etoposide at start phase 3 for second line treatment

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts


Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......